GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Allogene Therapeutics Inc (NAS:ALLO) » Definitions » Float Percentage Of Total Shares Outstanding

ALLO (Allogene Therapeutics) Float Percentage Of Total Shares Outstanding : 72.13% (As of Mar. 23, 2025)


View and export this data going back to 2018. Start your Free Trial

What is Allogene Therapeutics Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Allogene Therapeutics's float shares is 156.71 Mil. Allogene Therapeutics's total shares outstanding is 217.26 Mil. Allogene Therapeutics's float percentage of total shares outstanding is 72.13%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Allogene Therapeutics's Insider Ownership is 6.95%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Allogene Therapeutics's Institutional Ownership is 89.87%.


Allogene Therapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Allogene Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=156.71/217.26
=72.13%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Allogene Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Allogene Therapeutics Inc (NAS:ALLO) » Definitions » Float Percentage Of Total Shares Outstanding
Traded in Other Exchanges
N/A
Address
210 East Grand Avenue, South San Francisco, CA, USA, 94080
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.
Executives
David D Chang director, officer: President and CEO C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Deborah M. Messemer director C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Earl Martin Douglas officer: GENERAL COUNSEL BIOMIMETIC THERAPEUTICS, INC., 389 NICHOL MILL LANE, FRANKLIN TN 37067
Zachary Roberts officer: EVP of R&D C/O INSTIL BIO, INC., 3963 MAPLE AVENUE, SUITE 350, DALLAS TX 75219
Geoffrey M. Parker officer: CHIEF FINANCIAL OFFICER 15 RIORDAN PLACE, MENLO PARK CA 94025
Timothy L. Moore officer: Chief Technical Officer C/O KITE PHARMA, INC., 2225 COLORADO AVE., SANTA MONICA CA 90404
Franz B Humer director 388 GREENWICH STREET, 17TH FLOOR, NEW YORK NY 10013
Arie Belldegrun director, 10 percent owner UCLA SCHOOL OF MEDICINE, 10833 LE CONTE 66-118 CHS BOX 951738, LOS ANGELES CA 9095-1738
Yinlin Jack Chen officer: SVP, Finance 210 EAST GRAND AVE, SOUTH SAN FRANCISCO CA 94080
Stephen Mayo director 2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Lillian Smith officer: VP, Corporate Counsel 210 EAST GRAND AVE, SOUTH SAN FRANCISCO CA 94080
Veer Bhavnagri officer: General Counsel C/O ALLOGENE THERAPEUTICS, INC., 210 E. GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Owen N. Witte director C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Rafael Amado officer: EVP of R&D and CMO 210 EAST GRAND AVE, SOUTH SAN FRANCISCO CA 94080
Alison Moore officer: Chief Technical Officer C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080

Allogene Therapeutics Headlines

From GuruFocus